Current bolus thermodilution workflows reduce the full indicator dilution curve to a single flow value, discarding the hemodynamic signal it contains. TRACER is a rigorous analytics platform that extracts mean transit time, residence time distributions, and model-fitted flow metrics from thermodilution curves in coronary physiology.
Request OverviewCurrent coronary bolus thermodilution workflows compute a single mean transit time using the Stewart-Hamilton equation. The full concentration-time curve — which encodes mixing, dispersion, and flow structure — is discarded. This leaves hemodynamically meaningful signal on the table.
TRACER accepts thermodilution or CFD concentration curves, applies validated analytical methods, and outputs a rich set of flow metrics for coronary physiology research.
Extracts residence time distributions from raw indicator dilution curves, recovering mean transit time and distributional shape beyond conventional single-value estimates.
Fits validated transport and dispersion models to thermodilution signals, quantifying mixing and flow structure in coronary physiology.
Accepts both computational fluid dynamics concentration curves and legacy clinical thermodilution data in a unified analysis pipeline.
Structured case management with per-case goodness-of-fit metrics, typed validation, and project-level persistence.
TRACER is at the validation stage. Evidence to date spans software, computation, bench, and clinical data.
Functional analysis pipeline supporting residence time distribution computation and model fitting across CFD and patient data input modes.
CFD-derived concentration curves used to benchmark model fitting accuracy against established goodness-of-fit criteria.
Physical thermodilution experiments informing model behavior under controlled flow conditions.
Early application to legacy coronary thermodilution datasets from clinical settings, establishing feasibility in patient data.
We are actively seeking collaborators for pilot validation, discussing grant opportunities, and speaking with investors aligned with coronary diagnostics. Tell us about your interest and we'll reach out.
We work with clinical partners, academic collaborators, and early-stage investors.